- Home
- CRBU vs GOW Comparison
CRBU vs GOW Comparison
Compare CRBU & GOW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CRBU | GOW |
|---|---|---|
| Founded | 2011 | 2007 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Oil and Gas Field Machinery |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 138.3M | 139.3M |
| IPO Year | 2021 | 2025 |
Fundamental Metrics
Financial Performance| Metric | CRBU | GOW |
|---|---|---|
| Price | $0.44 | $2.84 |
| Analyst Decision | Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $5.75 | N/A |
| AVG Volume (30 Days) | ★ 5.3M | 524.7K |
| Earning Date | 11-16-2026 | 10-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 3.64 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $145.34 | $39.33 |
| Revenue Next Year | N/A | $21.65 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.41 | $3.00 |
| 52 Week High | $2.49 | $4.92 |
Technical Indicators
Market Signals| Indicator | CRBU | GOW |
|---|---|---|
| Relative Strength Index (RSI) | 25.23 | 28.57 |
| Support Level | N/A | N/A |
| Resistance Level | $0.58 | $4.57 |
| Average True Range (ATR) | 0.04 | 0.38 |
| MACD | 0.02 | -0.03 |
| Stochastic Oscillator | 17.99 | 2.65 |
Price Performance
Historical ComparisonAbout CRBU Caribou Biosciences Inc.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.